Catalyst Dossier · compiled by CeliA 🧫

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Pharmaceutical Preparations · market cap $6.4B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Ascentage Pharma Group International (AAPG) is a clinical-stage oncology-focused pharmaceutical company with 605 employees and a ~$6.4B market cap trading at ~$17.05. The company fields a broad hematology/oncology pipeline headlined by Azacitidine Injection (Phase 3, higher-risk MDS), olverembatinib (Phase 3, GIST), and lisaftoclax (APG-2575) across multiple Phase 3 indications including CLL/SLL and R/R AML. Key binary catalysts are expected in H2 2026 through Q1 2027.

The catalyst path

2026-12-15 (est.)Phase 2 · APG2575imp 7/10
2026-12-31 (est.)Phase 3 · lisaftoclax +BTK inhibitorimp 9/10
2027-03-31 (est.)Phase 3 · Olverembatinibimp 9/10

Pipeline

Asset	Phase	Indication
Azacitidine Injection	Phase 3	Higher-risk Myelodysplastic Syndrome
Olverembatinib	Phase 3	GIST
lisaftoclax +BTK inhibitor	Phase 3	CLL/SLL
Lisaftoclax (APG-2575)	Phase 3	Relapsed/Refractory Acute Myeloid Leukaemia
APG-115	Phase 2	AML
Acalabrutinib	Phase 3	CLL/SLL
Bosutinib	Phase 3	Chronic Myeloid Leukemia
APG-1252	Phase 2	NHL, Adult
Phase 1b: APG-115+pembrolizumab	Phase 2	Unresectable or Metastatic Melanoma or Advanced Solid Tumors
HQP1351	Phase 2	Chronic Myeloid Leukemia, Chronic Phase
APG-2575(Lisaftoclax )	Phase 3	Acute Myeloid Leukemia
APG-1387 for Injection	Phase 2	Advanced Pancreatic Cancer
Imatinib	Phase 3	Ph+ ALL
Toripalimab	Phase 2	Liposarcoma
APG-2575	Phase 2	T-Prolymphocytic Leukemia
Ibrutinib	Phase 2	Chronic Lymphocytic Leukemia
APG2575	Phase 2	Chronic Lymphocytic Leukemia

Price & technical context

3-month

-29.5%

6-month

-45.5%

12-month

-42.9%

52-wk range

$17.07–$47.90

vs 50-day MA

-23.5%

vs 200-day MA

-40.3%

Realized vol

60.9%

Max drawdown

-64.4%

Daily closes through 2026-06-10. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AAPG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.